When is the conference call hosted by Tyra Biosciences?

Tyra Biosciences will host a conference call and webcast regarding interim clinical results of TYRA-300 on October 25, 2024, at 8:00 am ET.

What clinical results will be discussed during the conference call?

The conference will present interim clinical results from the SURF301 Phase 1/2 study of TYRA-300 in metastatic urothelial cancer.

Who will be joining the conference call to provide insights?

Gary Steinberg, MD, a Professor of Urology at Rush University Medical Center, will be participating in the call along with Tyra's management team.

How can participants join the conference call and webcast?

Interested participants can access the live webcast on Tyra's 'For Investors' page on their website or register in advance to join via telephone.

What is the focus and location of Tyra Biosciences?

Tyra Biosciences is a clinical-stage biotechnology company focused on precision medicines targeting FGFR biology and is based in Carlsbad, California.

Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET

10/23/24 4:05:00 PM ET

$TYRA

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $TYRA alert in real time by email

CARLSBAD, Calif., Oct. 23, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it will host a conference call and webcast on October 25, 2024 at 8:00 am ET to share interim clinical results of TYRA-300 from the SURF301 Phase 1/2 study in metastatic urothelial cancer (mUC). These data will be presented in a late-breaking oral presentation at the 36^th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics, being held October 23-25, 2024, in Barcelona, Spain.

Gary Steinberg, MD, Professor of Urology, Department of Urology, Rush University Medical Center, will be joining members of TYRA's management team on the call and will be available during Q&A.

Conference Call Information

TYRA is hosting a conference call and webcast on October 25, 2024, at 8am ET to review the interim clinical data demonstrated with TYRA-300 in mUC. Participants may access a live webcast of the call and the associated slide presentation on the "For Investors" page of the TYRA website at https://ir.tyra.bio. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the Company's website for at least 90 days.

About Tyra Biosciences

Tyra Biosciences, Inc. (NASDAQ:TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. TYRA is based in Carlsbad, CA.

For more information about our science, pipeline and people, please visit www.tyra.bio and engage with us on LinkedIn.

Contact:

Amy Conrad

[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-to-host-conference-call-on-interim-clinical-data-of-tyra-300-from-surf301-phase-12-study-on-october-25-2024-at-8am-et-302285111.html

SOURCE Tyra Biosciences

Get the next $TYRA alert in real time by email

Recent Analyst Ratings for

$TYRA

Date	Price Target	Rating	Analyst
10/18/2024	$22.00 → $31.00	Neutral → Buy	BofA Securities
8/15/2024	$33.00	Overweight	Piper Sandler
12/15/2023	$25.00 → $15.00	Buy → Neutral	BofA Securities
6/30/2023	$27.00	Outperform	Wedbush
2/3/2023	$17.00	Outperform	Oppenheimer
6/23/2022	$12.00	Buy	H.C. Wainwright
3/8/2022	$31.00 → $27.00	Hold → Buy	Jefferies
11/8/2021	$19.00 → $31.00	Buy → Hold	Jefferies

More analyst ratings

Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET

Chat with this insight

Q&A

When is the conference call hosted by Tyra Biosciences?

What clinical results will be discussed during the conference call?

Who will be joining the conference call to provide insights?

How can participants join the conference call and webcast?

What is the focus and location of Tyra Biosciences?

Recent Analyst Ratings for $TYRA

$TYRA Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Fuhrman Alan bought $151,954 worth of shares (9,500 units at $16.00), increasing direct ownership by 284% to 12,849 units (SEC Form 4)

$TYRA Market Insights

Live Market Insights

Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday

Oppenheimer Reiterates Outperform on Tyra Biosciences, Maintains $28 Price Target

Wedbush Reiterates Outperform on Tyra Biosciences, Maintains $28 Price Target

$TYRA SEC Filings

SEC Form 144 filed by Tyra Biosciences Inc.

SEC Form 8-K filed by Tyra Biosciences Inc.

Tyra Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure

$TYRA Press Releases

Fastest customizable press release news feed in the world

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)

Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)